Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy in stage-IV NSCLC.

Martin Reck1, Ulrich Gatzemeier

  • 1Department of Thoracic Oncology, Hospital Grosshansdorf, Center of Pneumology and Thoracic Surgery, Woehrendamm 80, D-22927 Grosshansdorf, Germany. dr.martin.reck@web.de

Lung Cancer (Amsterdam, Netherlands)
|November 24, 2004
PubMed
Summary

New chemotherapy regimens for non-small cell lung cancer (NSCLC) show improved response rates and reduced toxicity. Pemetrexed offers similar efficacy to docetaxel with fewer side effects in advanced NSCLC treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026
Same author

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

JAMA oncology·2026
Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same author

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Clinical lung cancer·2026

Area of Science:

  • Medical Oncology
  • Thoracic Oncology
  • Pharmacology

Background:

  • Cisplatin-based chemotherapy has improved survival in advanced and metastatic non-small cell lung cancer (NSCLC).
  • Various novel combination regimens have been investigated to enhance treatment efficacy and tolerability.
  • Third-generation regimens aim to balance efficacy with reduced toxic side effects.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of novel chemotherapy regimens in advanced and metastatic NSCLC.
  • To compare third-generation regimens against classic combinations and monotherapy.
  • To assess the activity and safety profile of the antifolate Pemetrexed relative to docetaxel.

Main Methods:

  • Review of randomized trials comparing different chemotherapy regimens for NSCLC.

Related Experiment Videos

  • Analysis of response rates, time to progression, survival, and toxic side effects.
  • Comparative assessment of two-drug regimens, monotherapy, and best supportive care (BSC).

    • Main Results:

    • Third-generation regimens demonstrated comparable efficacy to each other, with improved response rates and time to progression versus classic combinations.
    • While survival benefits were modest, toxic side effects were significantly reduced with newer regimens.
    • Two-drug regimens were more effective than monotherapy but associated with increased toxicity.
    • Monotherapy improved quality of life and survival compared to BSC.
    • Pemetrexed showed comparable activity to docetaxel but with significantly reduced toxicities.

    Conclusions:

    • Novel chemotherapy combinations, particularly third-generation regimens, offer improved outcomes and tolerability in advanced NSCLC.
    • Pemetrexed represents a promising alternative to docetaxel due to its similar efficacy and improved safety profile.
    • Treatment selection should consider the balance between efficacy, toxicity, and impact on quality of life for NSCLC patients.